ByTrending Posts
Biotech Licensing Soars to $137B in 2025 –…
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
China Dominates 70% of Global AI Drug Patents:…
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China…
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital…
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution…
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution…
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline…
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing…
Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication…
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Trending Posts
Latest Stories
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market…
How Does Bristol Myers Squibb Secure Multi-Billion Dollar Growth Through 8 Key Oncology Catalysts by 2030?
Bristol Myers Squibb strategically positions for next-decade dominance through its deep pipeline featuring 5 multi-billion-dollar assets (pumitamig, iberdomide, mezigdomide,…
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology…
Gallery
